| FORM 990, PART III, LINE 4A: |
CURING CATASTROPHIC DISEASES IN CHILDREN IS A MULTI-TRILLION-DOLLAR, MULTI-YEAR GLOBAL PROBLEM AND ALSAC AND ST. JUDE MUST CONTINUE OUR WORK NO MATTER WHAT HAPPENS WITH THE ECONOMY, THE MARKET, FUNDRAISING OR IN THE EVENT OF A DISASTER. IT COSTS NEARLY $2 BILLION A YEAR TO RUN ST. JUDE AND THE COST IS ESTIMATED TO GROW TO $2.2 BILLION BY 2027. ST. JUDE IS A SPECIALTY RESEARCH HOSPITAL FOR CHILDREN, NOT A GENERAL CHILDREN'S HOSPITAL SO NONE OF THE CUTTING-EDGE RESEARCH COSTS AND MANY OF THE EXTENSIVE TREATMENTS AND SERVICES WE PROVIDE ARE NOT COVERED BY INSURANCE, AND MAY NOT BE IN THE FUTURE. UNLIKE OTHER HOSPITALS THAT RECEIVE 90-95% OPERATING REVENUES FROM INSURANCE RECOVERIES AND PATIENT COPAYS, THE MAJORITY OF OUR FUNDING COMES FROM GENEROUS DONORS AND INVESTMENT INCOME TO SUPPORT NEEDS NOW AND IN THE FUTURE. IN THE YEARS AHEAD, AN ESTIMATED 89% OF THE FUNDS NECESSARY TO RUN ST. JUDE MUST BE RAISED BY ALSAC FROM GENEROUS DONORS. WHEN ST. JUDE OPENED ITS DOORS IN 1962, CHILDHOOD CANCER WAS CONSIDERED INCURABLE. SINCE THEN, ST. JUDE HAS HELPED PUSH THE OVERALL SURVIVAL RATE FROM 20% TO MORE THAN 80%, AND WE WON'T STOP UNTIL NO CHILD DIES FROM CANCER. TODAY, ST. JUDE IS LEADING THE WAY THE WORLD UNDERSTANDS, TREATS, AND DEFEATS CHILDHOOD CANCER AND OTHER LIFE-THREATENING DISEASES. ST. JUDE IS THE FIRST AND ONLY NATIONAL CANCER INSTITUTE-DESIGNATED COMPREHENSIVE CANCER CENTER DEVOTED SOLELY TO CHILDREN. ST. JUDE IS ALSO THE FIRST WORLD HEALTH ORGANIZATION (WHO) COLLABORATING CENTRE FOR CHILDHOOD CANCER. IN 2021, IN PARTNERSHIP WITH THE WHO, ST. JUDE ANNOUNCED A SIX-YEAR, $200 MILLION INITIATIVE TO INCREASE DELIVERY OF HIGH-QUALITY CHEMOTHERAPY MEDICINES FREE OF CHARGE TO CHILDREN IN LOW- AND MIDDLE-INCOME COUNTRIES. THIS REPRESENTS THE LARGEST FINANCIAL COMMITMENT EVER MADE FOR A GLOBAL EFFORT IN CHILDHOOD CANCER MEDICINES. IN 2021, A ST. JUDE CLINICAL TRIAL ANNOUNCED A SIGNIFICANT ADVANCEMENT IN OUTCOMES FOR CHILDREN WITH HIGH-RISK NEUROBLASTOMA. THIS NEW THERAPY, DEVELOPED AT ST. JUDE, DELIVERS AN INCREASE IN SURVIVAL RATES OF MORE THAN 20 PERCENTAGE POINTS, TO 74 PERCENT. PRIOR TO THIS BREAKTHROUGH, THE SURVIVAL RATE HAD REMAINED AT APPROXIMATELY 51 PERCENT FOR A DECADE. ST. JUDE SHARES THE BREAKTHROUGHS IT MAKES TO HELP DOCTORS AND RESEARCHERS AT LOCAL HOSPITALS AND CANCER CENTERS AROUND THE WORLD IMPROVE THE QUALITY OF TREATMENT AND CARE FOR EVEN MORE CHILDREN. IN ADDITION TO CHILDHOOD CANCER, ST. JUDE PLAYS A CRITICAL LEADERSHIP ROLE IN GROUNDBREAKING STUDIES ON SICKLE CELL DISEASE, INFECTIOUS DISEASES, AND GENETIC DISORDERS. THESE EFFORTS ARE INSTRUMENTAL TO IMPROVING CARE FOR CHILDREN AROUND THE WORLD. A ST. JUDE PATIENT WAS THE FIRST IN THE WORLD TO BE CURED OF SICKLE CELL DISEASE WITH A BONE MARROW TRANSPLANT, AND ST. JUDE HAS ONE OF THE LARGEST PEDIATRIC SICKLE CELL PROGRAMS IN THE COUNTRY. AND ST. JUDE'S EFFORTS DON'T END WHEN TREATMENT STOPS. THE ST. JUDE AFTER COMPLETION OF THERAPY (ACT) PROGRAM IS THE LARGEST LONG-TERM FOLLOW-UP CLINIC FOR PEDIATRIC CANCER PATIENTS IN THE UNITED STATES AND ST. JUDE DOES THIS AT NO COST TO THE PATIENTS. THE CLINIC HELPS PATIENTS STAY HEALTHY AFTER ACTIVE TREATMENT ENDS AND HAS BEEN A PROTOTYPE FOR OTHER LONGER TERM FOLLOW-UP PROGRAMS. FORMER ST. JUDE PATIENTS ALSO ARE PARTICIPATING IN THE ST. JUDE LIFE STUDY, DESIGNED TO HELP ADULT SURVIVORS OF CHILDHOOD CANCER LEARN ABOUT ISSUES THAT AFFECT THEIR HEALTH AS WELL AS WAYS TO STAY HEALTHY. ST. JUDE IS ALSO HOME TO THE CHILDHOOD CANCER SURVIVOR STUDY, A COLLABORATIVE STUDY AMONG U.S. AND CANADIAN INSTITUTIONS THAT INCLUDES MORE THAN 20,000 CHILDHOOD CANCER SURVIVORS WITH THE AIM TO IMPROVE SURVIVORSHIP OUTCOME AND QUALITY OF LIFE. IN ADDITION, BRAIN TUMOR SCIENCE AND TECHNOLOGY AT ST. JUDE ARE AT THE CUTTING EDGE WORLDWIDE, AND ST. JUDE HAS ONE OF THE WORLD'S LEADING RESEARCH-BASED PEDIATRIC BRAIN TUMOR PROGRAMS. ST. JUDE IS THE COORDINATING CENTER OF THE NATIONAL PEDIATRIC BRAIN TUMOR CONSORTIUM, WHICH RECEIVES FUNDING FROM THE NATIONAL CANCER INSTITUTE. ST. JUDE'S COMMITMENT TO ADVANCING THE FRONTIERS OF RESEARCH IS EVIDENT IN THE 2021 OPENING OF THE NEW, $412M INSPIRATION4 ADVANCED RESEARCH CENTER (I4ARC), WHICH OFFERS SPACE FOR COMPUTATIONAL BIOLOGY, ARTIFICIAL INTELLIGENCE AND ONE OF THE MOST ADVANCED MICROSCOPES IN THE WORLD. IN ADDITION, THE I4ARC HOUSES LABS FOR IMMUNOLOGY, DEVELOPMENTAL NEUROBIOLOGY AND CELLULAR AND MOLECULAR BIOLOGY. THE CENTER CREATES AN INVITING SPACE FOR CLINICIANS, PHYSICIANS AND RESEARCH FROM ACROSS MULTIPLE DISCIPLINES TO COLLABORATE. |
| FORM 990, PART V, LINE 4B (CONTINUED): |
THE FINANCIAL ACCOUNTS IN THE FOREIGN COUNTRIES LISTED ON FORM 990, PART V, LINE 4B (AND SCHEDULE O) ARE RELATED TO INVESTMENTS. NO FINANCIAL ACCOUNTS FOR OPERATIONAL PURPOSES WERE MAINTAINED IN FOREIGN COUNTRIES. |
| FORM 990, PART VI, SECTION A, LINE 2 |
FAMILY RELATIONSHIP AMONG DIRECTORS: JOSEPH S. AYOUB, JR., ESQ. AND PAUL J. AYOUB, ESQ.; ROBERT A. BREIT, MD AND JOSEPH G. SHAKER. BUSINESS RELATIONSHIP AMONG DIRECTORS: JOSEPH C. SHAKER AND JOSEPH G. SHAKER; ANN M. DANNER AND CHRISTINA M. RASHID. |
| FORM 990, PART VI, SECTION B, LINE 11B |
EACH YEAR, THE AUDIT AND COMPLIANCE COMMITTEE AND OFFICERS OF THE BOARD ARE PROVIDED WITH A DRAFT COPY OF THE FORM 990 AND ALL REQUIRED SCHEDULES. THE AUDIT AND COMPLIANCE COMMITTEE MEETS WITH ITS TAX PREPARER TO REVIEW THE DRAFT FORM 990 BEFORE IT IS FILED WITH THE IRS. ADDITIONALLY THE COMPENSATION COMMITTEE OF THE BOARD IS PROVIDED WITH A DRAFT COPY OF THE COMPENSATION SECTIONS OF THE FORM 990, AND THE CONFLICT OF INTEREST COMMITTEE OF THE BOARD IS PROVIDED WITH A DRAFT COPY OF THE CONFLICT-OF-INTEREST SECTIONS OF THE FORM 990 FOR REVIEW BEFORE THE FINALIZED DOCUMENT IS FILED WITH THE IRS. EACH VOTING MEMBER OF THE BOARD IS PROVIDED WITH A FINAL COPY OF THE FORM 990 AND ALL REQUIRED SCHEDULES BEFORE IT IS FILED WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C |
THE ORGANIZATION MAINTAINS A CONFLICT OF INTEREST COMMITTEE OF THE BOARD OF DIRECTORS. IN ADDITION TO EDUCATION OF NEW BOARD MEMBERS ON THE CONFLICT OF INTEREST POLICY, THE ADMINISTRATOR TO THE BOARD/CHIEF GOVERNANCE OFFICER MONITORS CONFLICT MANAGEMENT PLANS (WHICH MAY INCLUDE CHANGING VENDORS, DIVESTITURE OF FINANCIAL INTERESTS, AND THE LIKE) TO ENSURE THEY ARE COMPLETED IN A TIMELY FASHION. UNDISCLOSED CONFLICTS ARE DISCOVERED, WHERE POSSIBLE, THROUGH THE ORGANIZATION'S CONTRACTING PROCESS. THIS IS TRUE FOR THE BOARD'S CONFLICT OF INTEREST POLICY AND FOR THE SEPARATE CONFLICT OF INTEREST POLICY APPLICABLE TO ALL ADMINISTRATION OF THE ORGANIZATION (POTENTIAL CONFLICTS OF THE ORGANIZATION ARE DISCUSSED AND RESOLVED AT A SENIOR-LEVEL CONFLICTS OF INTEREST COMMITTEE). POTENTIAL RESTRICTIONS RANGE FROM UNWINDING OR PROHIBITING A TRANSACTION, TO PREVENTING SOMEONE FROM PARTICIPATING IN A DELIBERATION, TO SIMPLE DISCLOSURE TO THE BOARD OF THE CONFLICTING INTEREST, DEPENDING ON THE FACTS AND CIRCUMSTANCES OF THE CONFLICT. |
| FORM 990, PART VI, SECTION B, LINE 15 |
AN INDEPENDENT COMPENSATION COMMITTEE OF THE BOARD, ADVISED BY AN INDEPENDENT OUTSIDE EXPERT, ANNUALLY REVIEWS THE REASONABLENESS OF THE TOTAL REMUNERATION PAID TO THE CEO, OTHER OFFICERS, AND CERTAIN OTHER EMPLOYEES. THE LAST REVIEW WAS COMPLETED IN DECEMBER 2022. THE BOARD'S EXECUTIVE TOTAL COMPENSATION PHILOSOPHY IS INTENDED TO SUPPORT THE ORGANIZATION'S OVERALL STRATEGY AND OBJECTIVES, ATTRACT AND RETAIN EMPLOYEES, LINK COMPENSATION TO PERFORMANCE AND THE ATTAINMENT OF THE ORGANIZATION'S OBJECTIVES, AND PROVIDE COMPENSATION AT A REASONABLE COST WHILE FULFILLING THE CHARITABLE MISSION OF THE ORGANIZATION. THE BOARD TARGETS TOTAL REMUNERATION BETWEEN THE 50TH AND 75TH PERCENTILES OF THE DEFINED COMPARATOR MARKET, WHILE GIVING DUE CONSIDERATION TO THE MISSION AND THE CHARITABLE NATURE OF THE ORGANIZATION. NO REVIEWED EMPLOYEE'S TOTAL REMUNERATION WAS OVER THE 75TH PERCENTILE FOR THE REPORTING YEAR. |
| FORM 990, PART VI, SECTION C, LINE 19 |
GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. |
| FORM 990, PART IX, LINE 26: |
WE CONDUCT A NUMBER OF ACTIVITIES, WHICH JOINTLY BENEFIT OUR EDUCATION, TRAINING, AND COMMUNITY SERVICE PROGRAM OBJECTIVES, AS WELL AS FUNDRAISING AND GENERAL AND ADMINISTRATIVE ACTIVITIES. THE EDUCATIONAL INFORMATION SHARED WITHIN THESE ACTIVITIES SUPPORT OUR MISSION TO LEAD THE WAY THE WORLD UNDERSTANDS, TREATS AND DEFEATS CHILDHOOD CANCER AND OTHER LIFE-THREATING DISEASES AND INCLUDE OUR TELEVISION AND RADIO PROGRAMS AND PLACEMENTS, DIRECT MAIL PROGRAM, AND CERTAIN OTHER FUNDRAISING AND PUBLIC AWARENESS EVENTS. IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD GUIDELINES, WE ALLOCATED A PORTION OF OUR FUNDRAISING EXPENSES TO PROGRAM SERVICE AND GENERAL AND ADMINISTRATIVE EXPENSES IN OUR COMBINED STATEMENTS OF FUNCTIONAL EXPENSES. |
Attach to Form 990 or 990-EZ.